2012
Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5
Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW. Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5. Journal Of Virology 2012, 87: 2401-2411. PMID: 23269796, PMCID: PMC3571396, DOI: 10.1128/jvi.02964-12.Peer-Reviewed Original ResearchConceptsCCR5 expression levelsF EnvsTransmitted/FounderHIV-1 envelope proteinCCR5 antagonist maravirocSingle genome amplificationExpression levelsSingle virus variantReplication-competent virusMVC resistanceFounder virusesChronic infectionCCR5 antagonistsT cellsHIV-1CCR5MaravirocControl virusPhysiologic levelsCCR5 conformationsVirus variantsEnvelope glycoproteinEnv proteinEnvInfectionTransmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW. Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7. PLOS Pathogens 2012, 8: e1002686. PMID: 22693444, PMCID: PMC3364951, DOI: 10.1371/journal.ppat.1002686.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, NeutralizingAntibodies, ViralCD4 AntigensCD4-Positive T-LymphocytesCells, CulturedCloning, MolecularHIV Envelope Protein gp120HIV InfectionsHIV-1Host-Pathogen InteractionsHumansIntegrinsMucous MembraneNeutralization TestsReceptors, CCR5Viral TropismVirus InternalizationVirus ReplicationConceptsF virusesInfectious molecular cloneMucosal HIV-1 acquisitionNew HIV-1 infectionsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Transmitted/FounderHIV-1 acquisitionHIV-1 vaccine designSubtype C HIVHIV-1 infectionSingle genome amplificationAnti-α4β7 antibodyVirus type 1V2 variable loopsChronic EnvsC HIVFounder virusesSexual transmissionChronic virusesGp120 subunitIntegrin α4β7Transmission fitnessSame CD4CD4
2011
Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins
Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW. Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins. Journal Of Virology 2011, 85: 8514-8527. PMID: 21715507, PMCID: PMC3165820, DOI: 10.1128/jvi.00736-11.Peer-Reviewed Original ResearchConceptsMucosal barrierF EnvsNeutralization sensitivitySingle-round infectivity assaysHuman immunodeficiency virus type 1Immunodeficiency virus type 1Enhanced neutralization sensitivityTransmitted/FounderHIV-1 envelope glycoproteinHIV-1 transmissionIntact mucosal barrierClade B EnvVirus type 1Chronic EnvsHIV-IgDendritic cellsCoreceptor tropismFounder virusesSexual transmissionEnv phenotypeAntibody b12Chronic controlEffective vaccineNew infectionsEnv trimers